Allogeneic transplant: Hematopoietic cells collected from an HLA-compatible sibling, family member, or unrelated donor.
Apheresis: The removal of normal or abnormal cells or plasma from the blood.
Autologous transplant: A patient’s hematopoietic cells are collected when the patient is in remission.
Graft versus host disease (GVHD): A reaction of immunocompetent T-cells from the donor that attack the recipient's skin, gut, liver, and hematopoietic cells.
Graft versus tumor effect: Transplanted T-cells attacking and killing cancer cells in the recipient.
CD34: The antigen found on uncommitted hematopoietic stem cells and early progenitor cells of the hematopoietic system.
Chimerism: The donor cells in the transplant recipient's peripheral blood and/or the bone marrow.
Donor lymphocyte infusion (DLI): A technique to prevent graft rejection.
Haplotype identical transplant: A transplant from a sibling or parent that matches 50% of the HLA genes of the patient.
Histocompatibility/human leukocyte antigens (HLA): Genetically determined antigens found on the surface of cell membranes that identify a cell as "self" or "non-self."
Minimal residual disease: The presence of neoplastic cells without clinical or morphologic evidence of disease.
Myeloablative therapy: Immunosuppressive therapy using chemotherapy and radiation therapy to reduce rejection of the HSC transplant.
Nonmyeloablative therapy: Suppression of graft versus host disease with increased graft versus tumor.
